Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Anticancer autophagy inhibitors attract ‘resurgent’ interest

Credit: Vicky Summersby/Springer Nature Limited

Access options

Rent or buy this article

Prices vary by article type



Prices may be subject to local taxes which are calculated during checkout

Nature Reviews Drug Discovery 18, 408-410 (2019)


Updates & Corrections

  • Correction 01 May 2019: The text describing a single-arm skin cancer study evaluating trametinib plus Novartis’s BRAF inhibitor dabrafenib with the addition of hydroxychloroquine for patients with BRAF-mutant melanoma has been revised to reflect that the study is still ongoing rather than completed.


Latest on:

Nature Careers


Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing


Quick links